Loncar Cancer Immunotherapy ETF (CNCR): Price and Financial Metrics ETF
CNCR Price/Volume Stats - 7 Best ETFs for the NEXT Bull Market
| Current price | $15.20 | 52-week high | $17.96 |
| Prev. close | $15.27 | 52-week low | $9.22 |
| Day low | $15.03 | Volume | 18,700 |
| Day high | $15.21 | Avg. volume | 27,925 |
| 50-day MA | $15.53 | Dividend yield | N/A |
| 200-day MA | $13.22 |
CNCR Stock Price Chart Interactive Chart >
Loncar Cancer Immunotherapy ETF (CNCR) ETF Bio
The investment objective of the Loncar Cancer Immunotherapy ETF seeks to replicate the Loncar Cancer Immunotherapy Index. The index was developed by a top biologist and includes large pharmaceutical and growth-oriented biotechnology firms that are focused on improving cancer treatments.
CNCR ETF Info
| Issuer | Range ETFs |
| Expense Ratio | 0.79% |
| Underlying Index | Range Cancer Therapeutics Index |
| Asset Class | Equity |
| Sector | Health & Biotech ETFs |
| Assets Under Management (AUM) | 17.94M |
| Net Asset Value (NAV) | $15.20 |
| Options? | Yes |
| Total Holdings | N/A |
CNCR Top Holdings
| Symbol | Company | % of Total |
CNCR Price Returns
| 1-mo | 5.85% |
| 3-mo | -6.86% |
| 6-mo | 42.72% |
| 1-year | 13.43% |
| 3-year | -44.62% |
| 5-year | -18.38% |
| YTD | 12.84% |
| 2023 | -1.89% |
| 2022 | -42.31% |
| 2021 | -19.24% |
| 2020 | 36.53% |
| 2019 | 24.22% |